{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:55:26Z","timestamp":1761238526087,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We elucidate the role of p21\/Waf-1, a cyclin-dependent kinase inhibitor, on the oncolytic infection and replication cycle of adenovirus by studying both mRNA and adenoviral proteins expression. We found that infection in the absence of p21 causes a significant increase in adenoviral genomes and late gene expression. Similarly, the oncolytic adenoviral infected p21\u2212\/\u2212 cells have earlier formation of replication foci and robust replication kinetics that were not observed in the wild type p21\/Waf-1 intact cells. These findings suggest a culmination that the presence of intact p21 in host cells causes defects in the oncolytic viral life cycle which results in the production of immature and noninfectious particles.<\/jats:p>","DOI":"10.3390\/cancers10060202","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T11:21:20Z","timestamp":1529061680000},"page":"202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production"],"prefix":"10.3390","volume":"10","author":[{"given":"Naseruddin","family":"H\u00f6ti","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara Jane","family":"Johnson","sequence":"additional","affiliation":[{"name":"James Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-646X","authenticated-orcid":false,"given":"Wasim H.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","article-title":"Use of replicating oncolytic adenoviruses in combination therapy for cancer","volume":"10","author":"Chu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.cgt.7700542","article-title":"Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes","volume":"9","author":"Hermiston","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2217\/14796694.2.1.137","article-title":"Current developments in adenovirus-based cancer gene therapy","volume":"2","author":"Rein","year":"2006","journal-title":"Future Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ncponc0044","article-title":"Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies","volume":"1","author":"Keith","year":"2004","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_5","first-page":"43","article-title":"Interleukin-6 modulated conditionally replicative adenovirus as an antitumor\/cytotoxic agent for cancer therapy","volume":"5","author":"Rancourt","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_6","first-page":"2576","article-title":"Prostate-specific expression of the diphtheria toxin a chain (dt-a): Studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven dt-a adenoviral-mediated gene transfer","volume":"62","author":"Li","year":"2002","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ymthe.2006.07.009","article-title":"Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy","volume":"14","author":"Hoti","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1128\/MCB.16.3.737","article-title":"P21 disrupts the interaction between CDK2 and the e2f-p130 complex","volume":"16","author":"Shiyanov","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/375159a0","article-title":"Cell-cycle inhibition by independent CDK and PCNA binding domains in p21cip1","volume":"375","author":"Luo","year":"1995","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/cgt.2010.15","article-title":"Armoring crads with p21\/Waf-1 shrnas: The next generation of oncolytic adenoviruses","volume":"17","author":"Hoti","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/cgt.2009.29","article-title":"Rna interference-mediated knockdown of p21(waf1) enhances anti-tumor cell activity of oncolytic adenoviruses","volume":"16","author":"Shiina","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.1128\/JVI.75.20.9844-9856.2001","article-title":"Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells","volume":"75","author":"Chattopadhyay","year":"2001","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1099\/0022-1317-80-2-381","article-title":"The adenoviral E1A oncoproteins interfere with the growth-inhibiting effect of the CDK-inhibitor p21(CIP1\/WAF1)","volume":"80","author":"Keblusek","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1128\/JVI.00820-12","article-title":"Replication of minute virus of mice in murine cells is facilitated by virally induced depletion of p21","volume":"86","author":"Adeyemi","year":"2012","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1128\/JVI.75.8.3613-3625.2001","article-title":"Degradation of p21cip1 in cells productively infected with human cytomegalovirus","volume":"75","author":"Chen","year":"2001","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1101\/gad.11.16.2090","article-title":"Inhibition of CDK activity and PCAN-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein","volume":"11","author":"Funk","year":"1997","journal-title":"Genes Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI28971","article-title":"Primitive hematopoietic cells resist HIV-1 infection via p21","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_18","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0042-6822(83)90274-X","article-title":"Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein","volume":"128","author":"Reich","year":"1983","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1002\/j.1460-2075.1994.tb06837.x","article-title":"Adenovirus replication and transcription sites are spatially separated in the nucleus of infected cells","volume":"13","author":"Pombo","year":"1994","journal-title":"EMBO J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"Johnson","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10123","DOI":"10.1128\/JVI.01102-12","article-title":"Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model","volume":"86","author":"Yakimovich","year":"2012","journal-title":"J. Virol."},{"key":"ref_23","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.mt.6300223","article-title":"Androgen receptor attenuation of AD5 replication: Implications for the development of conditionally replication competent adenoviruses","volume":"15","author":"Hoti","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1091\/mbc.10.7.2119","article-title":"The C-terminal domain of p21 inhibits nucleotide excision repair in vitro and in vivo","volume":"10","author":"Cooper","year":"1999","journal-title":"Mol. Biol. Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:08:51Z","timestamp":1760195331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["cancers10060202"],"URL":"https:\/\/doi.org\/10.3390\/cancers10060202","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2018,6,15]]}}}